Business Context and Reporting Period
This Form 8-K filing by SS Innovations International, Inc. (SSII) was submitted on July 14, 2026. The report discloses the appointment of a new Chief Financial Officer (CFO) effective August 3, 2026.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on executive compensation and employment terms.
- Base Compensation: $440,000 annual base salary.
- Equity Grant: 750,000 stock options under the 2026 Incentive Stock Plan.
- Vesting Schedule: 250,000 shares vest on the first anniversary; the remaining 500,000 shares vest in 23 monthly installments of 20,833 shares, with a final installment of 20,841 shares.
- Bonus: Eligible for an annual cash bonus based on performance criteria.
Material Changes
The primary material change is the leadership transition in the finance function. Sarah M. Romano is appointed as the new CFO, replacing the prior incumbent (not named in this text). Ms. Romano brings over two decades of experience, most recently serving as CFO and Treasurer of Vicarious Surgical Inc. (April 2025 – July 2026), and previously as CFO for Entero Therapeutics, Inc. and Kiora Pharmaceuticals, Inc.
Outlook, Risks, and Management Commentary
Management commentary is limited to the announcement of the appointment and the qualifications of the new CFO. The filing notes that the employment agreement includes customary confidentiality, assignment of proprietary rights, non-competition, and non-solicitation provisions. An indemnification agreement will also be executed on the effective date. No specific financial guidance or risk factors regarding the company's operations are detailed in this specific report.
Investor Verification Checklist
- Verify the effective date of the CFO transition (August 3, 2026) and the departure date of the previous CFO.
- Review the full Employment Agreement (Exhibit 10.1) for specific performance criteria tied to the annual cash bonus.
- Confirm the strike price and expiration terms of the 750,000 stock options granted under the 2026 Incentive Stock Plan.
- Assess the impact of the new CFO's background in biopharmaceuticals and robotics on SSII's strategic direction.